Based on the key indicators related to Intellia Therapeutics' liquidity, profitability, solvency, and operating efficiency, Intellia Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Intellia Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 80.9 M, whereas Other Liabilities is forecasted to decline to about 38.1 M. Key indicators impacting Intellia Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Intellia Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Intellia Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Intellia Therapeutics.
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.
Intellia Therapeutics Stock Summary
Intellia Therapeutics competes with Editas Medicine, Caribou Biosciences, Crispr Therapeutics, Verve Therapeutics, and Beam Therapeutics. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Intellia Therapeutics's current stock value. Our valuation model uses many indicators to compare Intellia Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intellia Therapeutics competition to find correlations between indicators driving Intellia Therapeutics's intrinsic value. More Info.
Intellia Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Intellia Therapeutics' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intellia Therapeutics' earnings, one of the primary drivers of an investment's value.
Intellia Therapeutics Systematic Risk
Intellia Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Intellia Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Intellia Therapeutics correlated with the market. If Beta is less than 0 Intellia Therapeutics generally moves in the opposite direction as compared to the market. If Intellia Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Intellia Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Intellia Therapeutics is generally in the same direction as the market. If Beta > 1 Intellia Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Intellia Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intellia Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Intellia Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.51
At present, Intellia Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Intellia Therapeutics February 16, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Intellia Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Intellia Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Intellia Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Intellia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Intellia Therapeutics's daily price indicators and compare them against related drivers.
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.